Dr. Mikhail Blagosklonny’s Revelation To A Longer Life

Dr. Mikhail Blagosklonny is a professor of Oncology at the Roswell Park Cancer Institute and had studied and conducted research in the area of cancer and its therapies, as well as the subject of aging and increasing the life span. Dr. Blagosklonny is well known for advocating for and spearheading the research for a drug called Rapamycin, which is considered to be a drug used in the fight against cancer, as well as contribution to increasing the human life span. To provide some background information on this drug, Rapamycin, also known as Sirolimus, it was first isolated on Bacterium found on Easter, Island bak in 1972. When discovered, it was first used an as anti-fungal agent. It was then abandoned as an anti-fungal, as further research showed that it possessed immunosuppressive and anti proliferative properties at tremendous levels. Immunosuppressive drugs are given to patients undergoing an organ transplant to prevent the body from rejecting the new organ. In such cases, patients can develop kidney disease, as a lot of these drugs can have an adverse affect on the kidneys over a long period of time.

Rapamycin is different from these drugs, as it shows lower levels of toxins that are harmful to the kidney, thus, making this a safer drug. Dr. Blagosklonny’s ongoing research has shown that Rapamycin aides in enhancing the immunity in the body to help battle the growth of tumors, promoting regression in those tumors at the same time. For these reasons, this drug serves as a great benefit to those patients who have undergone an organ transplant in the prevention of cancer. Although there is no conclusive evidence, it’s believed that this drug can also increase the human life span. In fact, when tested on elderly patients who took the influenza vaccine, initial results showed an immunological rejuvenation.

Dr. Blagosklonny continues his research in hopes of killing cancer cells without killing the good cells that help rejuvenate the mind, along with the body. No only does he want to cure cancer and expand the human life expectancy, but he would like to be able to provide this to patients who may not have the financial ability to participate in certain cancer treatments, because they are too expensive. He feels that cancer treatment should not have to be both excruciating and expensive as cancer treatment is at the present time. Dr. Blagosklonny has made great progress with his research and has been a tremendous influence in his field of expertise. He continues his research and hopes that he will inspire others to join him on his journey and continues where he may leave off, in hopes of creating a cost-effective treatment of a cure to cancer.

Eric Lefkofsky Is on a Mission to Find a Cure for Cancer

Eric Lefkofsky knows how to create a successful startup. He has taken a number of startups public, and managed to make a lot of money along the way. As such, he is an undisputed tech founder that is making an impact on the world. Unfortunately, his wife received a cancer diagnosis and his mission in life changed. A cancer diagnosis can be devastating, even confusing. Once over the shock, people often look for answers that are elusive. Those suffering from blood cancer along with their loved ones end up with far more questions than answers.

Lefkofsky has channeled his genius into taking a data-driven approach to curing cancer. The secret is learning to leverage machine learning and genomic sequencing to understand a patient’s tumor growth. It is disruptive technology, and positions itself to change how the medical industry peers inside the human body at a molecular level. There will come a time when doctors will be able to guide medicine applications and treatments with precision.

Even a professional like Lefkofsky strains at the thought of managing a new startup. However, Tempus, his new company, was born out of a personal problem that begged for a solution. His education offers some insights as to why he is able to bring ideas to fruition. Eric Lefkofsky presently serves as an adjunct professor at the University of Chicago. He graduated from the University of Michigan and went on to receive a Juris Doctor from the University of Michigan Law School. He has a gifted mind that utilizes his diverse education experience.

Lefkofsky is also worth $1.7 billion dollars. As such, he is more than willing to put hundreds of millions of dollars of his own money into projects. This gives him an edge that positions him to be a mover and shaker in the world.

To know more visit @: chicago.curbed.com/2015/1/6/10005148/groupon-ceo-eric-lefkofsky-the-man-behind-195m-home-sale